We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Groundbreaking Blood Test Detects Celiac Disease in Patients Without Gluten Exposure

By LabMedica International staff writers
Posted on 10 Jun 2025

Getting a reliable diagnosis for coeliac disease has long required patients to endure weeks of consuming gluten—a painful process for many already following gluten-free diets. More...

Now, a groundbreaking blood test could eliminate this need by detecting gluten-specific T cells, allowing clinicians to identify coeliac disease even in patients who have been avoiding gluten.

Researchers at Walter and Eliza Hall Institute (WEHI, Victoria, Australia), along with industry partner Novoviah Pharmaceuticals (Brisbane City, Australia) set out to develop a non-invasive, reliable diagnostic method for coeliac disease that works regardless of a patient’s current diet, streamlining the path to diagnosis and care. The test builds on WEHI’s 2019 discovery that the immune marker interleukin 2 (IL-2) spikes in the blood of people with coeliac disease shortly after gluten is consumed. Using this insight, the team designed an “in-tube” blood test that stimulates patient blood samples with gluten. If IL-2 levels rise in response, it indicates the presence of coeliac disease. Unlike conventional serology or biopsy-based testing, this method doesn’t require patients to resume eating gluten.

In the new study published in Gastroenterology, researchers evaluated blood samples from 181 participants, including individuals with treated and untreated coeliac disease, non-coeliac gluten sensitivity, and healthy controls. After a day of in-tube gluten exposure, the test detected coeliac disease with 90% sensitivity and 97% specificity—even in participants strictly avoiding gluten. These results highlight its strong diagnostic performance and potential real-world value. The test may be especially valuable for detecting silent or asymptomatic coeliac disease and identifying individuals at risk of severe reactions to gluten.

With up to 80% of coeliac cases globally still undiagnosed, and existing tests ineffective without regular gluten intake, this innovation could significantly improve early detection and long-term outcomes. The WEHI researchers are now working with Novoviah Pharmaceuticals to validate the test across broader populations and gather real-world data. They hope its adoption in clinical pathology labs will follow, once ultrasensitive cytokine testing becomes more widely available.

“There are likely millions of people around the world living with undiagnosed coeliac disease simply because the path to diagnosis is difficult, and at times, debilitating,” said Associate Professor Jason Tye-Din, Head of WEHI’s Coeliac Research Laboratory. “This new test promises to simplify and speed up accurate diagnosis, while also avoiding the suffering that comes with eating gluten for extended periods to reactivate coeliac disease. By eliminating the need for a gluten challenge, we’re addressing one of the biggest deterrents in current diagnostic practices. This test could be a game-changer, sparing thousands of people the emotional and physical toll of returning to gluten. It's a major step towards faster, safer diagnosis.”

Related Links:
WEHI 
Novoviah Pharmaceuticals


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.